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Abstract
Heat	 shock	 protein	 105	 (HSP105)	 is	 overexpressed	 in	 many	 cancers,	 including	
colorectal	cancer	(CRC)	and	esophageal	cancer	(EC).	We	carried	out	a	phase	I	clinical	
trial	of	HLA‐A24‐	and	HLA‐A2‐restricted	HSP105	peptide	vaccines	in	patients	with	
CRC	 or	 EC.	 In	 this	 additional	 study	 of	 the	 trial,	 we	 examined	 the	 immunological	
efficacy	of	the	novel	vaccine.	Thirty	patients	with	advanced	CRC	or	EC	underwent	
HSP105	peptide	 vaccination.	 Immunological	 responses	were	 evaluated	by	 ex	 vivo	
and	in	vitro	γ‐interferon	enzyme‐linked	immunospot	assays	and	their	correlation	with	
patients’	 prognosis	was	 analyzed.	 The	HSP105	peptide	 vaccines	 induced	peptide‐
specific	 CTLs	 in	 15	 of	 30	 patients.	 Among	HLA‐A24	 patients	 (n	 =	 15),	 7	 showed	
induction	of	CTLs	only	ex	vivo,	whereas	among	HLA‐A2	patients	(n	=	15),	4	showed	
the	induction	ex	vivo	and	6	in	vitro.	Heat	shock	protein	105‐specific	CTL	induction	
correlated	with	suppression	of	cancer	progression	and	was	revealed	as	a	potential	
predictive	biomarker	for	progression‐free	survival	(P	=	.008;	hazard	ratio	=	3.03;	95%	
confidence	interval,	1.34‐6.85)	and	overall	survival	(P	=	.025;	hazard	ratio	=	2.72;	95%	
confidence	interval,	1.13‐6.52).	Production	of	cytokines	by	HSP105	peptide‐specific	
CTLs	was	observed	at	 the	 injection	 sites	 (skin)	 and	 tumor	 tissues,	 suggesting	 that	
HSP105‐specific	CTLs	not	only	accumulated	at	vaccination	sites	but	also	infiltrated	
tumors.	Furthermore,	we	established	2	HSP105	peptide‐specific	CTL	clones,	which	
showed	HSP105‐specific	 cytokine	 secretion	 and	 cytotoxicity.	Our	 results	 suggest	
that	 the	 HSP105	 peptide	 vaccine	 could	 induce	 immunological	 effects	 in	 cancer	
patients	and	improve	their	prognosis.
K E Y W O R D S
cancer	vaccine,	cytokine,	cytotoxic	T	lymphocyte,	heat	shock	protein	105,	human	leukocyte	
antigen
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1  | INTRODUC TION
Colorectal	 cancer	 is	 the	 third	most	 common	 cancer	 type	 and	 the	
second	leading	cause	of	cancer‐related	deaths.1	Although	CRC	prog‐
nosis	has	improved	with	the	progress	of	surgery,	chemotherapy,	and	
molecular	targeted	drugs,	it	still	remains	poor.2	Immune	checkpoint	
inhibitors	have	shown	effectiveness	against	microsatellite	 instabil‐
ity‐high	colon	cancer;	however,	their	activity	is	 limited	to	this	sub‐
set	 of	 cancer	 patients.3,4	 Esophageal	 cancer	 is	 the	 seventh	 most	
common	cancer	type	and	the	sixth	leading	cause	of	cancer‐related	
deaths;5	however,	unlike	CRC,	EC	is	sensitive	to	few	antineoplastic	
agents.	It	is	expected	that	for	both	EC	and	CRC,	prognosis	could	be	
improved	with	the	development	of	immunotherapeutic	approaches.
Stress‐response	HSP105	has	been	 identified	as	a	biomarker	of	
colon cancer.6	Our	previous	results	indicate	that	HSP105	is	specif‐
ically	overexpressed	in	various	human	cancers	such	as	CRC	(54/64,	
84.4%),	pancreatic	cancer	(17/17,	100%),	EC	(12/14,	85.7%),	pharyn‐
geal	cancer	(8/8,	100%),	breast	cancer	(13/15,	86.7%),	and	melanoma	
(53/67,	 79.1%),	 but	 not	 in	 normal	 tissues	 except	 for	 the	 testes.7,8 
Heat	shock	protein	105	was	shown	to	inhibit	cancer	cell	apoptosis9 
and	animal	studies	on	the	HSP105	DNA	vaccine	and	HSP105‐pulsed	
dendritic	cells	revealed	that	HSP105	could	be	a	novel	promising	TAA	
in	cancer	immunotherapy.10,11
For	HSP105	immunotargeting,	it	is	necessary	to	identify	HLA	epi‐
topes.	We	focused	on	the	HLA‐A24‐encoding	gene,	for	which	60%	of	
Japanese	(95%	of	whom	have	HLA‐A*24:02)	and	20%	of	Caucasians	
are	positive,12,13	and	on	HLA‐A2,	the	most	common	HLA	class	I	allele	
in	the	Caucasian	population	also	found	in	40%	of	Japanese.12,14	As	a	
result,	we	identified	HLA‐A24‐	and	HLA‐A2‐restricted	HSP105	pep‐
tide	epitopes:	A24‐1	(NYGIYKQDL)	and	A24‐7	(EYVYEFRDKL)	and	
A2‐7	(RLMNDMTAV)	and	A2‐12	(KLMSSNSTDL)	and	revealed	that	
HSP105‐specific	CTLs	reactive	against	at	least	1	of	the	4	peptides	
were	present	in	67%	(14/21)	of	CRC	patients.15
Based	on	these	data,	we	undertook	a	phase	I	clinical	trial	of	the	
HSP105‐derived	 peptide	 vaccine	 for	 30	 patients	 with	 advanced	
CRC	and	EC	positive	for	1	or	more	of	HLA‐A*24:02,	02:01,	02:06,	or	
02:07	alleles	(manuscript	in	prep.).	Within	this	trial,	we	undertook	an	
additional	investigation	to	clarify	the	immunological	effectiveness	of	
HSP105	peptide	vaccines.
Here,	we	report	the	results	of	this	 immunological	study,	which	
indicate	that	HSP105	peptide‐based	vaccines	caused	accumulation	
of	 HSP105‐specific	 CTLs	 in	 peripheral	 blood,	 injection	 sites,	 and	
tumor	tissues,	suggesting	that	CTL	induction	could	be	a	prognostic	
biomarker	in	vaccinated	patients	with	advanced	CRC	and	EC.
2  | MATERIAL S AND METHODS
2.1 | Study design
This	 research	was	 undertaken	 as	 an	 additional	 study	 of	 a	 phase	 I	
clinical	 trial	 of	 HSP105‐derived	 peptide	 vaccine.	 Fifteen	 patients	
carrying	the	HLA‐A24	gene	received	HLA‐A24‐restricted	HSP105‐
derived	 peptides	 (A24‐1	 and	A24‐7)	 and	 15	 carrying	 the	HLA‐A2	
gene	 received	 HLA‐A2‐restricted	 HSP105‐derived	 peptides	 (A2‐7	
and	A2‐12)	(Table	S1).	Peptide	vaccines	were	given	with	an	adjuvant	
(Montanide	 ISA‐51	VG)	by	 intradermal	 injection	 (3	mg	per	 time)	 in	
the	axilla	every	7	days	for	a	maximum	of	1	year;	the	treatment	was	
discontinued	if	disease	progression	or	deterioration	of	the	patient's	
general	condition	was	observed.	All	patients	gave	written	informed	
consent;	 they	 were	 coded	 and	 fully	 anonymized.	 The	 study	 was	
approved	by	 the	Ethics	Committee	of	 the	National	Cancer	Center	
and	conformed	to	the	ethical	guidelines	of	the	1975	Declaration	of	
Helsinki.
2.2 | Evaluation of clinical response
Tumor	 size	 was	 assessed	 by	 computed	 tomography	 or	 magnetic	
resonance	imaging	before	vaccination	and	every	4	weeks	after	the	
first	vaccination.	Tumor	responses	were	evaluated	according	to	the	
RECIST	guideline	(version	1.1).16
2.3 | Peripheral blood collection
Peripheral	blood	samples	(30	mL)	were	obtained	from	CRC	and	EC	
patients	before	and	every	2	weeks	after	 the	first	vaccination.	The	
PBMCs	were	isolated	by	density	gradient	centrifugation	using	Ficoll‐
Paque	 (Pharmacia),	 frozen	 at	 −80°C,	 and	 stored	 in	 liquid	 nitrogen	
until	use.
2.4 | Cell lines
Human	 colon	 cancer	 cell	 line	 SW620	 (high	 HSP105	 expression,	
HLA‐A*02:01/A*24:02)	and	human	liver	cancer	cell	line	HepG2	(low	
HSP105	 expression,	 HLA‐A*02:01/A*24:02)	 were	 used	 as	 target	
cells.	 Transporter	 associated	 with	 antigen	 processing‐deficient	
human	lymphoblastoid	T2	(HLA‐A*02:01)	and	T2A24	(HLA‐A*24:02)	
cells	pulsed	with	appropriate	HSP105	peptides	or	HIV	peptides	at	
room	temperature	for	1	h	were	also	used	as	CTL	targets.	All	cell	lines	
were	preserved	in	our	laboratory;	they	were	cultured	in	RPMI‐1640	
or	 DMEM	 (Sigma)	 supplemented	 with	 10%	 heat‐inactivated	 FBS	
(Gibco)	 and	 1%	 penicillin	 and	 streptomycin	 (Gibco)	 at	 37°C	 in	 a	
humidified	atmosphere	containing	5%	CO2.
2.5 | Ex vivo IFN‐γ ELISPOT assay
The	 BD	 ELISPOT	 kit	 (BD	 Biosciences)	 was	 used	 according	 to	 the	
manufacturer's	 instructions.	Noncultured	 PBMCs	 (5	 ×	 105	 per	well)	
were	incubated	with	peptide	antigens	(10	μg/mL)	for	20	hours	at	37°C	
and	 5%	 CO2.	 The	 following	 HSP105	 antigens	 were	 used:	 HLA‐A2‐
restricted	 A2‐7	 (RLMNDMTAV)	 or	 A2‐12	 (KLMSSNSTDL)	 for	 HLA‐
A2‐positive	 PBMCs	 and	 HLA‐A24‐restricted	 A24‐1	 (NYGIYKQDL)	
or	 A24‐7	 (EYVYEFRDKL)	 for	 HLA‐A24‐positive	 PBMCs.	 The	
PBMCs	 incubated	 with	 HLA‐A2‐restricted	 HIV19‐27	 (TLNAWVKVV)	
or	 HLA‐A*24:02‐restricted	 HIV583‐591	 (RYLKDQQLL)	 peptides	
(ProImmune)	were	used	as	negative	control.	The	number	of	CTL	spots	
was	calculated	automatically	by	the	Eliphoto	system	(Minerva	Tech).	
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To	 eliminate	 nonspecific	 immune	 responses	 unrelated	 to	 HSP105	
peptides,	 the	 number	 of	 spots	 produced	 by	 HSP105‐specific	 CTLs	
was	determined	by	subtracting	the	number	of	spots	generated	against	
HLA‐matched	HIV	peptides	from	that	against	HSP105	peptides;	if	HIV	
peptides	produced	more	than	100	spots	and	the	difference	between	
HSP105	and	HIV	peptides	was	 less	 than	30	 spots,	 the	 results	were	
excluded.	All	analyses	were	carried	out	in	duplicate.
2.6 | Induction of HSP105 peptide‐specific CTLs 
from PBMCs and in vitro IFN‐γ ELISPOT assay
The	 PBMCs	 (2	 ×	 106	 per	 well)	 were	 cultured	 with	 HSP105	 A2‐7,	
A2‐12,	A24‐1,	or	A24‐7	(10	μg/mL)	in	RPMI‐1640	supplemented	with	
10%	FBS,	recombinant	human	IL‐2	(50	IU/mL;	Novartis	Pharma),	and	
IL‐15	(10	ng/mL;	PeproTech)	for	14	days.	CD8+	T	cells	were	isolated	
using	human	CD8	microbeads	(Miltenyi	Biotec)	and	analyzed	with	the	
BD	ELISPOT	kit;	T2	and	T2A24	cells	pulsed	with	the	corresponding	
HSP105	 peptides	 and	 HLA‐matched	 HIV	 peptides	 were	 used	 as	
targets.	The	isolated	CD8+	T	cells	were	cocultured	with	each	group	
of	target	cells	at	the	E/T	cell	ratio	of	0.2	for	20	hours	at	37°C	and	
5%	CO2.	The	number	of	spots	was	calculated	automatically	by	the	
Eliphoto	system,	and	the	results	showing	more	than	20	spots	against	
HIV	peptides	 and	 less	 than	10‐spot	 differences	 between	HSP105	
and	HIV	peptides	were	excluded.	All	 analyses	were	 carried	out	 in	
duplicate.
2.7 | Dextramer staining
The	PBMCs	 stimulated	with	 each	peptide	were	 stained	with	HLA	
type‐matched	Dextramer‐RPE	for	10	minutes	at	room	temperature.	
HLA‐A*24:02	 Dextramer‐RPE	 (A24‐1,	 A24‐7,	 and	 HIV583‐591)	 and	
HLA‐A*02:01	Dextramer‐RPE	(A2‐7,	A2‐12,	and	HIV19‐27)	were	used.	
After	staining	with	FITC‐conjugated	anti‐CD8	Abs	(ProImmune)	for	
20	minutes	at	4°C,	PBMCs	were	analyzed	by	flow	cytometry	using	a	
FACSAria	cell	sorter	(BD	Biosciences).
2.8 | CD107a staining
CD8+	 T	 cells	 were	 incubated	with	 T2	 and	 T2A24	 cells	 pulsed	with	
HSP105	peptides	or	HLA	type‐matched	HIV	peptides	at	the	E/T	ratio	
of	 2	 in	 the	 presence	 of	 APC‐conjugated	 CD107a‐specific	 Abs	 (BD	
Biosciences)	for	3.5	hours	at	37°C	and	analyzed	by	flow	cytometry.
2.9 | Analysis of TILs
Harvested	tissues	were	cut	into	2‐mm	square	pieces	and	incubated	
in	 RPMI‐1640	 containing	 GlutaMax	 supplement	 (Thermo	 Fisher	
Scientific),	 10%	 human	 AB	 serum	 (Sigma),	 0.01%	 penicillin‐
streptomycin‐glutamine	 mixture	 (Thermo	 Fisher	 Scientific),	 2‐
mercaptoethanol	 (50	 μmol/L;	 Sigma),	 pyruvate	 (1	mmol/L;	 Gibco),	
and	 IL‐2	 (3000	 IU/mL)	 for	 14	 days	 at	 37°C	 and	 5%	 CO2.	 Tumor‐
infiltrating	 lymphocytes	 detected	 by	 the	 IFN‐γ	 ELISPOT	 assay	
were	incubated	with	HLA‐matched	HSP105	peptide‐pulsed	T2	and	
T2A24	 cells	 in	 the	 presence	 of	 APC‐conjugated	 anti‐CD107a	 Abs	
for	3.5	hours	at	37°C.	After	staining	with	FITC‐conjugated	anti‐CD8	
Abs	for	20	minutes	at	4°C,	TILs	were	analyzed	by	flow	cytometry.	
Supernatants	 were	 used	 to	 measure	 secretion	 of	 IL‐2,	 IFN‐γ,	 and	
TNF‐α	 (Cytometric	Bead	Array	Enhanced	Sensitivity	Flex	Sets;	BD	
Biosciences)	and	granzyme	B	(Cytometric	Bead	Array	Flex	Sets;	BD	
Biosciences).	The	data	were	analyzed	with	the	FCAP	Array	Software	
(version	3.0;	BD	Biosciences).
2.10 | Generation of CTL clones
The	 PBMC‐derived	 CD8+	 HSP105	 Dextramer+	 cells	 and	 tissue‐
derived	CD8+CD107a+	cells	were	sorted,	seeded	on	96‐well	plates	
(1	cell	per	well),	and	stimulated	with	 irradiated	 (100	Gy)	allogeneic	
PBMCs	 (8	 ×	 104	 per	 well)	 used	 as	 feeder	 cells	 in	 AIM‐V	medium	
(Thermo	Fisher	Scientific)	supplemented	with	10%	human	AB	serum,	
IL‐2	(100	IU/mL),	IL‐15	(10	ng/mL),	and	phytohemagglutinin‐P	(1	μg/
mL;	Wako)	for	14‐21	days.
2.11 | Cytotoxicity assay
Target	 cells	 labeled	 with	 calcein‐AM	 (Dojindo)	 for	 30	 minutes	 at	
37°C	were	cocultured	with	CTL	clones	for	4	hours	at	different	E/T	
ratios.	Fluorescence	was	measured	before	and	after	coculture	using	
the	 Terascan	 VPC	 system	 (Minerva	 Tech),	 and	 specific	 cytotoxic	
activity	was	calculated	as	previously	described.17
2.12 | Determination of recognition efficiency
Calcein‐AM‐labeled	T2	and	T2A24	cells	were	pulsed	with	different	
peptide	 concentrations	 (10−4‐10−14	 M	 at	 log	 increments)	 and	
incubated	with	CTL	clones	at	the	E/T	ratio	of	10.	After	4	hours,	CTLs	
were	 analyzed	 for	 recognition	 efficiency	 defined	 as	 the	 peptide	
concentration	 at	 which	 the	 concentration	 curve	 crosses	 the	 50%	
cytotoxicity	threshold.17
2.13 | Evaluation of HLA‐A2 restriction
Hepatitis	 B	 virus‐integrated	 human	 hepatocellular	 carcinoma	 cell	
line	 JHH‐7	 (low	 HSP105	 expression,	 HLA‐A*24:02+/A*31:01+)	
transfected	 with	 each	 HLA‐A2	 gene,	 JHH‐7/mock	 (HLA‐A2−),	
JHH‐7/A*02:01	 (HLA‐A*02:01+),	 JHH‐7/A*02:06	 (HLA‐A*02:06+),	
and	JHH‐7/A*02:07	(HLA‐A*02:07+)	was	used	as	the	target	cell	line.	
Detailed	 transfection	 methods	 are	 in	 accordance	 with	 previously	
described	methods.18	The	expression	of	HLA‐A2	in	each	cell	line	was	
evaluated	by	flow	cytometry	(Figure	S1).	These	cell	lines	were	used	
as	target	cells	after	pulsing	with	HSP105	A2‐7	peptide.
2.14 | Immunohistochemistry
Immunohistochemistry	staining	was	carried	out	using	mAbs	against	
HSP105	 (clone	 EPR4576;	 Epitomics),	 HLA	 class	 I	 (clone	 EMR8‐5;	
Hokudo),	PD‐L1	(clone	SP142;	SPRING),	CD8	(clone	1A5;	BioGenex),	
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and	 CD4	 (clone	 4B12;	 Dako)	 according	 to	 the	 manufacturers’	
protocols.	Quantitative	analysis	of	HSP105	expression	was	carried	
out	based	on	the	staining	 intensity	and	the	results	were	scored	as	
0,	1+,	2+,	and	3+.	The	HLA	class	I	expression	was	evaluated	based	
on	 the	proportion	of	stained	cells	and	staining	 intensity;	however,	
because	all	examined	cancer	tissues	had	a	high	proportion	of	stained	
cells	 (67%	 or	 more),	 they	 were	 classified	 based	 on	 the	 intensity.	
Expression	of	PD‐L1	was	scored	as	–	(0%)	or	+	(1%	or	more)	according	
to	 the	 percentage	 of	 positively	 stained	 areas	 relative	 to	 the	 total	
tumor	areas.	CD4+	and	CD8+	T	cells	in	tumors	were	counted	in	high	
power	fields	(×400)	and	the	average	numbers	were	calculated.
2.15 | Sequence analysis of TCR
T‐cell	receptor	sequences	of	CTL	clones	were	identified	as	previously	
described.19	 Briefly,	 cDNA	 was	 amplified	 using	 24	 TCR‐BV	 gene	
family‐specific	forward	primers	and	a	constant	region‐specific	reverse	
primer.	Thereafter,	PCR	products	were	amplified	by	seminested	PCR	
for	screening	the	BV	gene	family.	Polymerase	chain	reaction	products	
identified	using	specific	primers	were	sequenced.	The	international	
ImMunoGeneTics	 information	system	(IMGT)	database	site	 (http://
imgt.cines.fr)	was	used	to	 identify	 the	human	TCR‐BV	gene	family.	
Analysis	of	the	TCR	repertoire	of	HSP105	peptide‐specific	CTLs	in	
PBMCs	was	undertaken	by	Repertoire	Genesis	(Osaka,	Japan).
2.16 | Statistical analysis
Statistical	 analyses	 were	 carried	 out	 using	 R	 software	 (The	 R	
Foundation	 for	 Statistical	 Computing;	 http://r‐proje	ct.org).	
Categorical	data	were	compared	by	the	χ2	test	or	Fisher's	exact	test,	
and	continuous	data	were	compared	by	the	Mann‐Whitney	U	 test.	
Prognostic	 factors	were	evaluated	using	 the	 log‐rank	test	and	Cox	
proportional	hazard	models.	Spearman	rank	correlations	were	used	
for	correlation	analysis.	Statistical	significance	was	defined	at	P	<	.05.
3  | RESULTS
3.1 | Patient characteristics
Clinicopathological	 characteristics	 of	 patients	 are	 presented	 in	
Table	1.	Among	the	30	patients,	21	were	men	and	17	and	13	were	
diagnosed	 with	 EC	 and	 CRC,	 respectively.	 The	 average	 age	 was	
F I G U R E  1  Changes	in	the	frequencies	of	heat	shock	protein	105	(HSP105)	peptide‐specific	CTLs	before	and	after	vaccination.	A,	
Representative	images	of	samples	with	maximal	Δ	spot	numbers.	Patient	(Pt.)	numbers	are	given	on	the	top.	“Before”	and	“After”	indicate	
samples	taken	before	and	after	vaccination,	respectively.	B,	Graphs	show	time‐dependent	changes	in	Δ	spot	numbers	of	PBMCs	obtained	
before	and	every	2	wk	after	the	first	vaccination.	ELISPOT,	enzyme‐linked	immunospot;	IFN‐γ,	γ‐interferon
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63.0	 years	 (range,	 30‐77	 years),	 and	 the	median	 follow‐up	 period	
was	 5.0	months	 (range,	 0.8‐15.3	months).	 Eleven	 patients	 had	 SD	
and	16	had	progressive	disease	1	month	after	the	first	vaccination,	
according	to	RECIST.
3.2 | Immunological responses
We	evaluated	 the	 expression	 of	HSP105,	HLA	 class	 I,	 and	 PD‐L1	
in	primary	tumors	and	tumor	infiltration	of	CD4+	and	CD8+ T cells 
before	and	after	vaccination	(Tables	S2	and	S3	and	Figure	S2).	The	
expression	of	HSP105	and	HLA	class	 I	before	the	first	vaccination	
was	 observed	 in	 all	 analyzed	 patients	 (14/14,	 100%)	 and	 that	 of	
PD‐L1	was	detected	in	6	patients,	all	of	whom	had	EC.	Because	of	
objective	 difficulties	 in	 obtaining	 matching	 tumor	 samples	 before	
and	 after	 vaccination,	we	 could	 compare	 expression	 changes	only	
in	 3	 patients	 (nos.	 9,	 23,	 and	 24);	 nevertheless,	 HSP105	 levels	
declined	in	all	of	them	after	vaccination.	Despite	the	low	number	of	
analyzed	patients,	it	can	be	hypothesized	that	the	vaccination	led	to	
elimination	of	cancer	cells	with	strong	HSP105	expression.
To	 determine	 whether	 HSP105	 peptide	 vaccines	 induced	 the	
functional	activity	of	CTLs,	we	carried	out	IFN‐γ	ELISPOT	assays	in	
PBMCs	from	the	vaccinated	patients	(Figure	1	and	Table	1).	The	ex	
vivo	IFN‐γ	ELISPOT	results	indicated	that,	after	vaccination,	the	fre‐
quency	of	HSP105	peptide‐specific	CTLs	in	PBMCs	was	increased	
in	 11	 of	 30	 patients	 (37%);	 among	 them,	 7	 patients	 received	 the	
HLA‐A24	vaccine.	The	in	vitro	IFN‐γ	ELISPOT	results	showed	that	
HSP105	 peptide‐specific	 CTLs	 were	 induced	 in	 6	 patients	 (6/30,	
20%),	all	of	whom	received	the	HLA‐A2	vaccine.
3.3 | Heat shock protein 105‐specific CTLs could 
delay cancer progression and improve prognosis
We	 analyzed	 the	 correlation	 between	 HSP105‐specific	 CTL	
frequency	and	clinical	outcomes.	Mean	tumor	size	in	patients	with	
induced	HSP105‐specific	CTLs	(58.3	±	33.6	mm)	was	smaller	than	
that	 in	 patients	without	 the	 induction	 (88.7	 ±	 47.6	mm)	 (P	 =	 .04;	
Figure	 2A).	 The	 maximum	 increase	 in	 HSP105‐specific	 CTLs	
observed	in	ELISPOT	assays	significantly	negatively	correlated	with	
the	rate	of	tumor	increase	per	day	(r	=	−0.501,	P	<	.01;	Figure	2B).	
In	patients	with	HSP105‐specific	CTL	 frequencies	greater	 than	or	
equal	to	100	(n	=	10),	the	tumor	increase	per	day	ratio	(0.32	±	0.34)	
showed	an	especially	significant	decline	compared	to	that	in	patients	
F I G U R E  2  Correlation	between	heat	shock	protein	105	
(HSP105)‐specific	CTL	frequencies	and	clinical	outcomes.	A,	Spider	
plot	of	tumor	size	changes	during	HSP105	peptide	vaccination.	
CTL(+)	and	CTL(−)	indicate	patients	with	and	without	the	induction	
of	HSP105‐specific	CTLs,	respectively,	in	ex	vivo	and	in	vitro	
γ‐interferon	enzyme‐linked	immunospot	assays.	B,	Negative	
correlation	observed	between	maximum	numbers	of	HSP105‐
specific	CTL	spots	and	the	tumor	increase	ratio	per	day	calculated	
by	dividing	tumor	increase	values	by	the	number	of	observation	
days	(r	=	−0.501,	P	<	.01).	C,	Correlation	between	HSP105‐specific	
CTL	frequency	and	overall	survival	(OS)	(r	=	0.706,	P	<	.01)
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with	CTL	 frequencies	 less	 than	 100	 (0.94	 ±	 0.74;	P	 <	 .01).	 These	
data	 indicated	 that	 HSP105	 peptide	 vaccines	 might	 delay	 cancer	
progression	by	inducing	specific	CTLs	and	that	the	strength	of	the	
induction	was	 an	 important	 factor.	Moreover,	 the	CTL	 frequency	
also	correlated	with	OS	 (r	=	 .704,	P	<	 .01;	Figure	2C).	All	patients	
with	lower	spot	numbers	and	better	OS	(nos.	1,	8,	12,	15,	20,	and	
25)	 had	 good	 performance	 status	 (PS)	 and	 tended	 to	 be	 younger	
(Tables	1	and	S4).
We	also	examined	prognostic	factors	for	OS	and	PFS	(Table	2).	
Univariate	analysis	indicated	that	the	induction	of	HSP105‐specific	
CTLs	was	the	only	prognostic	factor	for	PFS	(–;	P	=	.004)	and	PS	(1;	
P	=	.004),	whereas	skin	reaction	(–;	P	=	.021)	and	CTL	induction	(–;	
TA B L E  2  Univariate	and	multivariate	analyses	of	correlations	between	clinical	and	immunological	factors	and	overall	survival	(OS)	and	
progression‐free	survival	(PFS)	among	patients	who	received	heat	shock	protein	105	(HSP105)	peptide	vaccine
Parameter
PFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR P value HR 95% CI P value HR P value HR 95% CI P value
Age,	years	(≥65/<65) 1.14 .737    1.08 .856    
Sex	(male/female) 1.89 .143    1.06 .899    
Tumor	type	(EC/CRC) 1.54 .261    1.26 .593    
HLA	(A24/A2) 1.11 .786    2.02 .107    
Tumor	size	(≥50/<50) 1.14 .742    2.50 .060    
Performance	status	
(0/1)
1.94 .133 1.59 0.65‐3.91 .312 4.84 .004 4.39 1.43‐13.50 .010
Skin	reaction	(+/−) 1.41 .389    2.64 .021    
Induction	of	HSP105‐
specific	CTLs	in	ex	vivo	
and/or	in	vitro	IFN‐γ 
ELISPOT	assays	(+/−)
3.21 .004 3.03 1.34‐6.85 .008 2.97 .013 2.72 1.13‐6.52 .025
CI,	confidence	interval;	CRC,	colorectal	cancer;	EC,	esophageal	cancer;	ELISPOT,	enzyme‐linked	immunospot;	HLA,	human	leukocyte	antigen;	HR,	
hazard	ratio;	IFN‐γ,	γ‐interferon.
F I G U R E  3  Cytokines	produced	by	heat	shock	protein	105	(HSP105)	peptide‐specific	CTLs	at	vaccine	injection	sites	and	in	tumor	
tissues.	CTLs	were	cocultured	with	T2	or	T2A24	cells	pulsed	with	HIV	peptide	or	HSP105	peptides	and	analyzed	for	cytokine	secretion	to	
supernatant;	phorbol	myristate	acetate	plus	ionomycin	(PMA)	was	added	as	positive	control.	Patient	(Pt.)	numbers	are	shown	at	the	top.	
White	bars	indicate	HSP105	peptide‐specific	cytokine	production.	Gzm,	granzyme	B;	IL,	interleukin;	TNF‐α,	tumor	necrosis	factor‐α
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P	=	.0013)	were	prognostic	factors	for	OS.	Furthermore,	in	multivari‐
ate	analysis,	CTL	induction	was	a	prognostic	factor	for	PFS	(P	=	.008;	
HR	=	3.03;	95%	CI,	1.34‐6.85)	and	OS	(P	=	.025;	HR	=	2.72;	95%	CI,	
1.13‐6.52)	and	PS	was	associated	with	OS	(P	=	.010;	HR	=	4.39;	95%	
CI,	1.43‐13.50).
3.4 | Heat shock protein 105‐specific CTLs 
accumulated at vaccine inoculation sites and tumors
Next,	 we	 examined	 the	 infiltration	 of	 HSP105‐specific	 CTLs	 into	
vaccine	inoculation	sites	and	tumors	based	on	cytokine	production	
(Figure	3	 and	Table	 S5).	Heat	 shock	protein	105‐specific	 cytokine	
release	after	vaccination	was	observed	in	the	skin	(patients	nos.	4,	8,	
13,	17,	and	23),	primary	tumor	(patient	no.	27),	metastasized	lymph	
node	(patient	no.	9),	and	lung	tissue	(patient	no.	24),	indicating	that	
HSP105‐specific	CTLs	migrated	not	only	 to	 the	 injection	sites	but	
also	 to	 tumors,	 including	metastatic	 lesions.	 In	patients	nos.	9,	24,	
and	27,	 the	 induction	of	HSP105‐specific	CTLs	was	also	observed	
in	PBMCs,	whereas	in	patients	nos.	4,	13,	and	17,	it	was	detected	at	
the	injection	sites	and	PBMCs,	and	in	patients	nos.	8	and	23	only	at	
the	injection	sites.
3.5 | Heat shock protein 105‐specific CTLs 
infiltrated into tumor tissue following peptide 
vaccination
In	 patient	 no.	 9,	 who	 was	 diagnosed	 with	 advanced	 EC	 and	 had	
the	HLA‐A*02:01	gene,	the	therapeutic	effect	was	classified	as	SD	
1	month	after	vaccination;	nevertheless,	he	developed	metastasis	to	
the	cervical	 lymph	node	and	vaccination	was	 terminated	after	 the	
fifth	 injection.	 The	 patient	 had	 insignificant	 increase	 of	 HSP105‐
specific	 CTLs	 ex	 vivo,	 but	 showed	 a	 remarkable	 induction	 of	
HSP105	A2‐7	peptide‐specific	CTLs	(246	of	5	×	105	PBMCs)	in	vitro	
(Figure	1).	We	 resected	 the	metastatic	 lymph	node	and	measured	
cytokine	release	by	infiltrated	HSP105	peptide‐specific	CTLs,	which	
showed	secretion	of	IL‐2,	IFN‐γ,	and	TNF‐α	(Figure	3).	Furthermore,	
immunohistochemistry	 revealed	 increased	 infiltration	 of	 CD8+ 
lymphocytes	 into	 the	 lymph	 node	 after	 vaccination	 (Figure	 4A	
and	 Table	 S3),	 indicating	 post‐vaccination	 changes	 in	 the	 tumor	
microenvironment.
To	assess	 the	 specificity	of	HSP105	 recognition	as	 an	antigen,	
TILs	from	lymph	node	tissue	were	incubated	with	high	concentration	
of	 IL‐2	 and	 analyzed	 for	 IFN‐γ	 production	 in	 response	 to	 T2	 cells	
pulsed	with	HSP105	A2‐7	 peptide	 (T2‐HSP105	A2‐7).	 The	 results	
indicated	that	IFN‐γ	secretion	was	increased,	and	an	HSP105	A2‐7‐
specific	CTL	clone	was	established	from	a	single	CD8+CD107a+ cell 
(Figure	4B).	This	CTL	clone	showed	HSP105	peptide‐specific	IFN‐γ 
secretion	 in	 response	 to	 T2‐HSP105	 A2‐7	 cells	 and	 SW620	 cells	
(high	HSP105	expression),	but	not	in	response	to	T2	cells	pulsed	with	
HIV19‐27	peptide	(T2‐HIV)	or	HepG2	cells	(low	HSP105	expression)	
(Figure	4C),	and	also	showed	cytotoxicity	against	T2‐HSP105	A2‐7	
cells	(Figure	4D).	The	avidity	of	the	established	clone	for	the	HSP105	
A2‐7	peptide	was	analyzed	by	the	ability	to	lyse	T2‐HSP105	A2‐7	or	
T2‐HIV	cells	pulsed	with	decreasing	concentrations	of	each	peptide,	
and	its	recognition	efficacy	was	determined	as	10−7	M	(Figure	4E).	
Moreover,	 82.7%	 and	 4.16%	 of	 the	 cloned	 CTLs	 showed	 CD107a	
expression	 in	 response	 to	 T2‐HSP105	 A2‐7	 and	 SW620	 cells,	 re‐
spectively	(Figure	4F),	suggesting	clone	degranulation,	and	showed	
IFN‐γ,	IL‐2,	and	TNF‐α	secretion	(Figure	4G).	These	results	indicated	
that	the	established	CTL	clone	specifically	recognized	the	HSP105	
peptide	 and	 exerted	 cytotoxicity	 against	 cells	 presenting	HSP105	
not	 only	 exogenously	 but	 also	 endogenously.	 Furthermore,	 the	
CTL	clone	produced	 IFN‐γ	as	opposed	to	not	only	JHH‐7/A*02:01	
but	 also	 JHH‐7/A*02:06,	 showing	 that	 it	 could	 recognize	 not	 only	
HSP105	A2‐7	peptide‐HLA‐A*02:01	complex	but	also	A*02:06	com‐
plex	(Figure	S3).
3.6 | Heat shock protein 105‐specific CTL clone 
could recognize HSP105‐expressing cancer cells
Patient	 no.	 21	 with	 advanced	 CRC	 and	 the	 HLA‐A*24:02	 gene	
received	the	vaccine	11	times	and	showed	long‐term	SD	according	
to	RECIST;	however,	the	vaccination	was	terminated	at	the	patient's	
request.	In	his	case,	we	observed	a	remarkable	increase	of	HSP105	
A24‐1	 peptide‐specific	 CTLs	 (312	 of	 5	 ×	 105	 PBMCs)	 in	 the	 ex	
vivo	 IFN‐γ	 ELISPOT	 assay	 (Figure	 1)	 and	 established	 an	 A24‐1‐
specific	 CTL	 clone	 from	 a	 single	 CD8+HSP105	A24‐1	Dextramer+ 
cell	after	 the	third	vaccination	 (Figure	S4A).	The	CTL	clone,	which	
showed	 99.9%	 CD8/HSP105	 Dextramer	 positivity,	 demonstrated	
cytotoxicity,	cytokine	secretion,	and	CD107a	expression	specifically	
F I G U R E  4   Immunological	monitoring	of	patient	no.	9	and	establishment	of	a	tissue‐derived	CTL	clone.	A,	Immunohistochemical	analysis	
of	heat	shock	protein	105	(HSP105)	and	CD8	expression	before	and	after	vaccination.	Magnification,	×200.	B,	Cervical	lymph	node	resected	
after	the	fifth	vaccination	(upper	left	panel)	showed	increased	number	of	HSP105	A2‐7	peptide‐specific	CTLs	in	the	γ‐interferon	(IFN‐γ)	
enzyme‐linked	immunospot	(ELISPOT)	assay	(upper	right	panels).	FACS	analysis	of	CD8+CD107a+	T	cells	showing	reactivity	against	T2	cells	
pulsed	with	an	HIV	peptide	(lower	left	panel)	or	the	HSP105	A2‐7	peptide	(lower	right	panel).	Single	CD8+CD107a+	T	cells	reactive	against	
the	HSP105	A2‐7	peptide‐pulsed	cells	were	used	to	establish	a	CTL	clone.	C,	IFN‐γ	production	by	the	CTL	clone	measured	by	the	IFN‐γ 
ELISPOT	assay.	T2	cells	pulsed	with	HSP105	A2‐7	or	HIV	peptides	and	SW620	and	HepG2	cells	were	used	as	targets	at	the	effector	/	target	
(E/T)	ratio	of	0.2.	D,	Cytotoxic	activity	of	the	CTL	clone	against	HIV	peptide‐	or	HSP105	A2‐7	peptide‐pulsed	T2	cells	was	measured	at	
the	E/T	ratios	of	3,	10,	and	30	by	the	cytotoxicity	assay.	E,	The	avidity	of	the	CTL	clone	was	tested	using	T2	cells	pulsed	with	different	
concentrations	of	HSP105	A2‐7	or	HIV	peptides;	E/T	ratio	of	10.	The	peptide	concentration	at	which	the	curve	crossed	the	50%	cytotoxicity	
line	(dotted)	was	defined	as	the	recognition	efficiency	of	the	clone.	F,	Surface	CD107a	expression	by	the	CTL	clone	was	analyzed	in	response	
to	the	indicated	target	cells.	G,	Production	of	IFN‐γ,	interleukin‐2	(IL‐2),	and	tumor	necrosis	factor‐α	(TNF‐α)	by	the	CTL	clone	(1.0	×	105 cells 
per	well)	after	24‐h	of	coculture	with	the	indicated	target	cells	(5	×	104	per	well).	Data	represent	the	mean	±	SD	of	2	measurements.	*P	<	.05
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against	 A24‐1‐pulsed	 T2A24	 cells	 and	 SW620	 cells;	 its	 A24‐1	
recognition	efficacy	was	10−8	M	(Figure	S4B‐F).
3.7 | Vaccine induced polyclonal peptide‐specific 
CTLs in PBMCs of vaccinated patients
We	 evaluated	 the	 clonality	 of	 peptide‐specific	 CTLs	 induced	
by	 vaccinations.	 Three	 other	 peptide‐specific	 CTL	 clones	 were	
established	 from	 the	 PBMCs	 of	 patient	 no.	 30	 (Figure	 S5A).	
Furthermore,	we	sorted	peptide‐specific	CTLs	(CD8+CD107a+	cells)	
in	 this	 patient's	 PBMCs	 for	 TCR	 repertoire	 analysis	 (Figure	 S5B).	
Consequently,	TCR	repertoire	analysis	 revealed	that	HSP105	A2‐7	
peptide‐specific	CTLs	 in	this	patient's	PBMCs	displayed	numerous	
patterns	of	V‐J‐CDR3	and	the	frequencies	of	the	same	TCR	sequence	
as	established	CTL	clones	were	41.5%,	8.1%,	and	0.1%,	respectively	
(Table	 S6),	 suggesting	 that	 polyclonal	 peptide‐specific	 CTLs	 were	
induced	in	PBMCs	through	vaccination.
4  | DISCUSSION
Immune	 checkpoint	 inhibitors	 and	 adoptive	 immunotherapy	 with	
tumor‐infiltrating	 CTLs	 have	 shown	 undoubted	 efficacy	 against	
malignant	 melanoma.20,21	 Peptide	 vaccine	 therapy	 could	 prolong	
survival	 of	 cancer	patients	 and	prevent	 tumor	 recurrence	without	
serious	 adverse	effects,	 thus	not	 interfering	with	patient's	 quality	
of	 life.22	 However,	 it	 seems	 difficult	 to	 achieve	 an	 anticancer	
therapeutic	 effect	 using	 only	 peptide‐based	 vaccines.	 In	 this	 trial	
of	 the	HSP105	peptide	vaccine,	we	did	not	observe	patients	with	
complete	or	partial	response,	but	there	were	cases	with	 long‐term	
SD.	Our	 results	 indicate	 that	 the	HSP105	peptide	vaccine	 induces	
anticancer	 immune	 reactivity	 and,	 therefore,	 deserves	 further	
evaluation.	However,	 previous	 analyses	 of	 established	CTL	 clones	
revealed	their	antitumor	effects	on	HSP105+	cell	lines	were	limited,	
and	 the	 clinical	 effect	 of	 the	 vaccine	 was	 inadequate,	 probably	
because	 these	 CTLs	 were	 established	 from	 the	 cells	 of	 patients	
already	 harboring	 antigen‐expressing	 cancer	 cells,	 suggesting	 the	
presence	of	an	immunosuppressive	mechanism	in	these	patients	or	
the	lack	of	the	high‐avidity	T‐cell	clones	in	these	patients,	based	on	
the	immunological	selection	for	self‐antigens.
Although	we	observed	the	induction	of	HSP105‐specific	CTLs	in	
PBMCs	in	only	50%	of	patients	(15/30),	it	was	associated	with	good	
prognosis	(higher	PFS	and	OS);	therefore,	the	future	goal	should	be	
the	increase	of	the	CTL	induction	rate.	The	developed	HSP105	pep‐
tide	vaccine	consists	of	a	mixture	of	2	short	peptides	(10	or	fewer	res‐
idues),	and	it	was	shown	that	CTLs	induced	by	short	peptide‐based	
vaccines	do	not	migrate	to	tumors,	 remaining	at	 injection	sites	and	
becoming	 immunologically	 tolerant	 through	 binding	 to	HLA	 class	 I	
presented	by	nonprofessional	APCs	that	do	not	express	costimula‐
tory	molecules.23,24	Consistent	with	these	observations,	in	our	study,	
patients	nos.	8	and	23	had	HSP105‐specific	CTLs	at	the	injection	sites	
but	not	among	PBMCs.	To	overcome	this	problem,	vaccination	with	
longer	peptides	that	could	induce	more	effective	immune	responses	
not	only	through	their	uptake	by	APCs	and	presentation	on	HLA	class	
ΙΙ	but	also	by	cross‐presentation	on	HLA	class	Ι	might	be	useful.24,25 
Furthermore,	we	 targeted	only	one	TAA,	HSP105,	whereas	clinical	
trials	of	peptide‐based	vaccines	targeting	several	TAAs	reported	in‐
creased survival.26‐28	 In	the	present	trial,	HSP105	expression	 in	tu‐
mors	decreased	after	 vaccination,	 suggesting	 that	 tumor	 cells	with	
high	HSP105	 levels	were	 removed,	 although	 those	with	 low	or	 no	
HSP105	expression	could	remain.	In	a	clinical	trial	of	a	GPC3‐target‐
ing	peptide	vaccine	as	adjuvant	therapy	for	hepatocellular	carcinoma,	
post‐vaccination	 recurring	 tumors	 showed	 low	GPC3	expression,29 
indicating	that	tumor	cells	lacking	the	targeted	TAA	could	remain	and	
regrow	after	vaccination.	Although	HSP105	is	a	very	specific	tumor	
antigen,	cancer	cells	are	highly	heterogeneous	and	combination	ther‐
apy	with	vaccines	targeting	multiple	TAAs	might	be	more	effective.
It	 should	 also	 be	 considered	 that	 tumor	 cells	 reduce	 their	 an‐
tigen	 presentation	 to	 escape	 from	 immunological	 surveillance.30 
Thus,	HLA	class	I	expression	is	decreased	or	absent	in	16%‐50%	of	
cancers.31	In	this	study,	we	established	HSP105‐specific	CTL	clones	
that	not	only	exerted	cytotoxicity	 against	HSP105	peptide‐pulsed	
cells	 in	 a	 concentration‐dependent	 manner	 but	 also	 recognized	
HSP105‐expressing	 cells,	 thus	 showing	HSP105‐related	 antitumor	
activity.	However,	cytotoxicity	might	not	be	enough	to	achieve	clin‐
ical	 effectiveness	 because	 of	 insufficient	 antigen	 presentation	 by	
cancer	cells.	Although	we	detected	HSP105‐specific	CTLs	not	only	
at	the	injection	sites	but	also	in	2	metastatic	tumors	and	1	primary	
tumor,	 indicating	 that	 intradermal	 peptide	 vaccination	 promoted	
tumor	infiltration	by	CTLs,	it	is	not	sufficient	to	achieve	the	desired	
antitumor	 effects.	 To	 overcome	 this	 issue,	 we	 are	 developing	 an	
intratumoral	 injection	method	 for	 peptide	 vaccine	 delivery,	which	
could	provide	stronger	antitumor	activity	than	conventional	skin	in‐
jection	and	cause	systemic	immune	responses,	inhibiting	the	growth	
of	metastasized	tumors.32,33	 It	was	shown	that	the	combination	of	
intratumoral	 peptide	 vaccination	with	 an	Ab	 blocking	PD‐1	 highly	
expressed	on	 the	surface	of	peptide‐specific	CTLs	augmented	an‐
ticancer	effects.34‐36	 It	 is	possible	that	vaccination	efficacy	can	be	
enhanced	 both	 in	 primary	 tumors	 and	 distant	metastatic	 sites	 by	
loading	the	peptide	directly	into	HLA	class	I	of	tumor	cells	by	intra‐
tumoral	injection	and	using	anti‐PD‐1	Abs,	which	we	expect	to	test	
in	a	future	trial.
It	is	thought	difficult	to	obtain	antigen‐specific	CTL	clones,	espe‐
cially	from	PBMCs	of	patients	with	cancer	(except	melanoma).37	Here,	
we	established	two	HSP105‐specific	CTL	clones	from	PBMCs	and	re‐
sected	tumors	using	HSP105‐Dextramer	and	CD107a	assays.	CD107a	
is	a	CTL	degranulation	marker	used	to	 isolate	CTLs	with	high	tumor	
antigen	 specificity	 from	PBMCs	 after	vaccination.37‐39	Although	our	
CTL	clones	showed	similar	avidity	(10−7 and 10−8	M,	respectively),	the	
clone	obtained	using	the	CD107a	assay	tended	to	have	higher	pep‐
tide‐specific	CD107a	 expression	 and	 cytokine	 secretion,	 suggesting	
that	this	assay	could	be	more	effective	for	isolation	of	functional	CTLs.	
However,	both	clones	showed	insufficient	cytotoxicity	against	cancer	
cells,	and	we	are	currently	establishing	CTL	clones	with	higher	avidity.
Furthermore,	administration	of	CTLs	with	engineered	TCRs	tar‐
geting	 cancer	 antigens	 has	 reported	 significant	 long‐term	 clinical	
     |  3059SHIMIZU et al.
responses40‐44;	 however,	 it	 requires	 isolation	 of	 patient‐derived	
high‐avidity	T‐cell	clones	specific	for	a	target	antigen	and	analysis	of	
their	TCR	genes,	which	is	rarely	achieved.45	In	the	present	study,	we	
successfully	established	2	highly	functional	CTL	clones	correspond‐
ing	to	different	HLA	types	and	analyzed	their	TCRαβ	genes	(data	not	
shown),	 suggesting	 that	 anticancer	 therapy	using	genetically	 engi‐
neered	CTLs	 has	 a	 potential	 in	 patients	with	HSP105‐positive	 tu‐
mors	of	different	HLA	types.
In	conclusion,	we	show	that	the	HSP105	peptide	vaccine	could	
induce	 functional	 tumor‐reactive	 CTLs	with	 high	HSP105‐peptide	
recognition	 efficiency.	 Although	 our	 study	 had	 a	 limitation	 as	 the	
sample	size	was	small,	to	the	best	of	our	knowledge,	this	is	the	first	
report	regarding	HSP105	as	a	target	for	cancer	immunotherapy.	In	
the	future,	we	plan	to	introduce	more	advanced	HSP105‐targeting	
treatment	 strategies,	 such	as	T‐cell	 therapy	using	engineered	TCR	
genes	from	HSP105‐specific	CTL	clones	and	intratumoral	injection	
together	with	immune	checkpoint	inhibitors.
ACKNOWLEDG MENTS
This	study	was	supported	 in	part	by	the	National	Cancer	Center	
Research	and	Development	Fund	(25‐7	and	28‐A‐8),	Japan	Agency	
for	 Medical	 Research	 and	 Development	 (AMED,	 grant	 no.	 JP	
16ck0106109	h0003),	and	by	Health	and	Labor	Science	Research	
Grants	 for	 Research	 for	 Promotion	 of	 Cancer	 Control	 Programs	
from	 the	 Ministry	 of	 Health,	 Labor,	 and	 Welfare,	 Japan.	 The	
authors	thank	Manami	Shimomura	and	Yukiko	Kozaki	for	technical	
assistance.
CONFLIC T OF INTERE S T
The	corresponding	author,	T.	Nakatsura	is	the	inventor	of	the	peptide	
vaccine	 patents.	 T.	Nakatsura	 and	 T.	 Yoshikawa	 are	 supported	 by	
fundamental	research	funding	from	Takeda	Pharmaceutical	Co.,	Ltd.	
The	other	authors	report	no	conflict	of	interest.
ORCID
Tetsuro Sasada  https://orcid.org/0000‐0002‐2313‐8833 
Hideaki Bando  https://orcid.org/0000‐0001‐5041‐2765 
Tetsuya Nakatsura  https://orcid.org/0000‐0003‐3918‐2385 
R E FE R E N C E S
	 1.	 Torre	LA,	Bray	F,	Siegel	RL,	et	al.	Global	cancer	statistics,	2012.	CA 
Cancer J Clin.	2015;65:87‐108.
	 2.	 Brenner	 H,	 Kloor	 M,	 Pox	 CP.	 Colorectal	 cancer.	 Lancet. 
2014;383:1490‐1502.
	 3.	 Le	 DT,	 Uram	 JN,	Wang	 H,	 et	 al.	 PD‐1	 Blockade	 in	 Tumors	 with	
Mismatch‐Repair	Deficiency.	N Engl J Med.	2015;372:2509‐2520.
	 4.	 Overman	MJ,	McDermott	R,	Leach	JL,	et	al.	Nivolumab	in	patients	
with	 metastatic	 DNA	 mismatch	 repair‐deficient	 or	 microsatellite	
instability‐high	colorectal	cancer	(CheckMate	142):	an	open‐label,	
multicentre,	phase	2	study.	Lancet Oncol.	2017;18:1182‐1191.
	 5.	 Ferlay	 J,	 Soerjomataram	 I,	Dikshit	 R,	 et	 al.	 Cancer	 incidence	 and	
mortality	 worldwide:	 sources,	 methods	 and	 major	 patterns	 in	
GLOBOCAN	2012.	Int J Cancer.	2015;136:E359‐386.
	 6.	 Nakatsura	T,	Senju	S,	Yamada	K,	et	al.	Gene	cloning	of	immunogenic	
antigens	overexpressed	 in	pancreatic	cancer.	Biochem Biophys Res 
Comm.	2001;281:936‐944.
	 7.	 Kai	 M,	 Nakatsura	 T,	 Egami	 H,	 et	 al.	 Heat	 shock	 protein	 105	
is	 overexpressed	 in	 a	 variety	 of	 human	 tumors.	 Oncol Rep. 
2003;10:1777‐1782.
	 8.	 Muchemwa	 FC,	 Nakatsura	 T,	 Fukushima	 S,	 et	 al.	 Differential	
Expression	of	Heat	Shock	Protein	105	 in	melanoma	and	melano‐
cytic	naevi.	Melanoma Res.	2008;18:166‐171.
	 9.	 Hosaka	S,	Nakatsura	T,	Tsukamoto	H,	et	al.	Synthetic	small	interfering	
RNA	targeting	heat	shock	protein	105	induces	apoptosis	of	various	
cancer	cells	both	in	vitro	and	in	vivo.	Cancer Sci.	2006;97:623‐632.
	10.	 Miyazaki	M,	Nakatsura	T,	Yokomine	K,	 et	 al.	DNA	vaccination	of	
HSP105	 leads	 to	 tumor	 rejection	 of	 colorectal	 cancer	 and	mela‐
noma	 in	mice	 through	 activation	of	 both	CD4	T	 cells	 and	CD8	T	
cells. Cancer Sci.	2005;96:695‐705.
	11.	 Yokomine	 K,	Nakatsura	 T,	Minohara	M,	 et	 al.	 Immunization	with	
heat	shock	protein	105‐pulsed	dendritic	cells	leads	to	tumor	rejec‐
tion	in	mice.	Biochem Biophys Res Comm.	2006;343:269‐278.
	12.	 Date	Y,	Kimura	A,	Kato	H,	et	al.	DNA	typing	of	 the	HLA‐A	gene:	
population	study	and	identification	of	four	new	alleles	in	Japanese.	
Tissue Antigens.	1996;47:93‐101.
	13.	 Ohmori	M,	Yasunaga	S,	Maehara	Y,	et	al.	DNA	typing	of	HLA	class	
I	 (HLA‐A)	and	class	 II	 genes	 (HLA‐DR,	 ‐DQ	and	 ‐DP)	 in	 Japanese	
patients	with	gastric	cancer.	Tissue Antigens.	1997;50:277‐282.
	14.	 Browning	M,	Krausa	P.	Genetic	diversity	of	HLA‐A2:	evolutionary	
and	functional	significance.	Immunol Today.	1996;17:165‐170.
	15.	 Sawada	Y,	Komori	H,	Tsunoda	Y,	et	al.	Identification	of	HLA‐A2	or	
HLA‐A24‐restricted	 CTL	 epitopes	 for	 potential	 HSP105‐targeted	
immunotherapy	in	colorectal	cancer.	Oncol Rep.	2014;31:1051‐1058.
	16.	 Eisenhauer	EA,	Therasse	P,	Bogaerts	J,	et	al.	New	response	evalua‐
tion	criteria	in	solid	tumours:	revised	RECIST	guideline	(version	1.1).	
Eur J Cancer.	2009;45:228‐247.
	17.	 Yoshikawa	T,	Nakatsugawa	M,	 Suzuki	 S,	 et	 al.	HLA‐A2‐restricted	
glypican‐3	peptide‐specific	CTL	clones	induced	by	peptide	vaccine	
show	high	avidity	and	antigen‐specific	killing	activity	against	tumor	
cells. Cancer Sci.	2011;102:918‐925.
	18.	 Tada	Y,	Yoshikawa	T,	Shimomura	M,	et	al.	Analysis	of	cytotoxic	T	
lymphocytes	 from	 a	 patient	 with	 hepatocellular	 carcinoma	 who	
showed	a	clinical	response	to	vaccination	with	a	glypican‐3‐derived	
peptide.	Int J Oncol.	2013;43:1019‐1026.
	19.	 Tanaka‐Harada	Y,	Kawakami	M,	Oka	Y,	 et	 al.	Biased	usage	of	BV	
gene	families	of	T‐cell	receptors	of	WT1	(Wilms’	tumor	gene)‐spe‐
cific	CD8	+	T	cells	in	patients	with	myeloid	malignancies.	Cancer Sci. 
2010;101:594‐600.
	20.	 Hamid	 O,	 Robert	 C,	 Daud	 A,	 et	 al.	 Safety	 and	 tumor	 responses	
with	 lambrolizumab	 (anti‐PD‐1)	 in	 melanoma.	 N Engl J Med. 
2013;369:134‐144.
	21.	 Gattinoni	 L,	 Powell	 DJ	 Jr,	 Rosenberg	 SA,	 et	 al.	 Adoptive	 immu‐
notherapy	 for	 cancer:	 building	 on	 success.	 Nat Rev Immunol. 
2006;6:383‐393.
	22.	 Melero	 I,	 Gaudernack	 G,	 Gerritsen	 W,	 et	 al.	 Therapeutic	 vac‐
cines	for	cancer:	an	overview	of	clinical	 trials.	Nat Rev Clin Oncol. 
2014;11:509‐524.
	23.	 Hailemichael	Y,	Dai	Z,	Jaffarzad	N,	et	al.	Persistent	antigen	at	vacci‐
nation	sites	induces	tumor‐specific	CD8⁺	T	cell	sequestration,	dys‐
function	and	deletion.	Nat Med.	2013;19:465‐472.
	24.	 Melief	CJ,	van	der	Burg	SH.	Immunotherapy	of	established	(pre)ma‐
lignant	disease	by	synthetic	long	peptide	vaccines.	Nat Rev Cancer. 
2008;8:351‐360.
	25.	 Van	Poelgeest	MI,	Welters	MJ,	van	Esch	EM,	et	al.	HPV16	synthetic	
long	 peptide	 (HPV16‐SLP)	 vaccination	 therapy	 of	 patients	 with	
3060  | SHIMIZU et al.
advanced	or	recurrent	HPV16‐induced	gynecological	carcinoma,	a	
phase	II	trial.	J Transl Med. 2013;11:88.
	26.	 Walter	S,	Weinschenk	T,	Stenzl	A,	et	al.	Multipeptide	immune	response
to	cancer	vaccine	IMA901	after	single‐dose	cyclophosphamide	asso‐
ciates	with	longer	patient	survival.	Nat Med.	2012;18:1254‐1261.
	27.	 Yoshitake	Y,	Fukuma	D,	Yuno	A,	et	al.	Phase	II	clinical	trial	of	mul‐
tiple	peptide	vaccination	 for	 advanced	head	and	neck	cancer	pa‐
tients	revealed	induction	of	 immune	responses	and	improved	OS.	
Clin Cancer Res.	2015;21:312‐321.
	28.	 Aruga	A,	Takeshita	N,	Kotera	Y,	et	al.	Long‐term	vaccination	with	
multiple	peptides	derived	from	cancer‐testis	antigens	can	maintain	
a	specific	t‐cell	response	and	achieve	disease	stability	in	advanced	
biliary	tract	cancer.	Clin Cancer Res.	2013;19:2224‐2231.
	29.	 Sawada	Y,	Yoshikawa	T,	Ofuji	K,	et	al.	Phase	II	study	of	the	GPC3‐
derived	peptide	vaccine	as	an	adjuvant	therapy	for	hepatocellular	
carcinoma	patients.	Oncoimmunology.	2016;5:e1129483.
	30.	 Khong	HT,	Restifo	NP.	Natural	selection	of	tumor	variants	in	the	gener‐
ation	of	“tumor	escape”	phenotypes.	Nat Immunol.	2002;3:999‐1005.
	31.	 Hicklin	DJ,	Marincola	FM,	Ferrone	S.	HLA	class	I	antigen	downregu‐
lation	in	human	cancers:	T‐cell	immunotherapy	revives	an	old	story.	
Mol Med Today.	1999;5:178‐186.
	32.	 Nobuoka	D,	Yoshikawa	T,	Fujiwara	T,	et	al.	Peptide	intra‐tumor	in‐
jection	for	cancer	immunotherapy:	enhancement	of	tumor	cell	anti‐
genicity	is	a	novel	and	attractive	strategy.	Hum Vaccin Immunother. 
2013;9:1234‐1236.
	33.	 Nobuoka	D,	Yoshikawa	T,	Takahashi	M,	et	al.	Intratumoral	peptide
injection	 enhances	 tumor	 cell	 antigenicity	 recognized	 by	 cyto‐
toxic	 T	 lymphocytes:	 a	 potential	 option	 for	 improvement	 in	 anti‐
gen‐specific	 cancer	 immunotherapy.	Cancer Immunol Immunother. 
2013;62:639‐652.
	34.	 Sawada	Y,	Yoshikawa	T,	Shimomura	M,	et	al.	Programmed	death‐1
blockade	 enhances	 the	 antitumor	 effects	 of	 peptide	 vaccine‐in‐
duced	 peptide‐specific	 cytotoxic	 T	 lymphocytes.	 Int J Oncol. 
2015;46:28‐36.
	35.	 Fourcade	J,	Sun	Z,	Pagliano	O,	et	al.	PD‐1	and	Tim‐3	regulate	the
expansion	of	tumor	antigen‐specific	CD8⁺	T	cells	induced	by	mela‐
noma vaccines. Can Res.	2014;74:1045‐1055.
	36.	 Wong	RM,	Scotland	RR,	Lau	RL,	et	al.	Programmed	death‐1	block‐
ade	enhances	expansion	 and	 functional	 capacity	of	 human	mela‐
noma	antigen‐specific	CTLs.	Int Immunol.	2007;19:1223‐1234.
	37.	 Rubio	V,	Stuge	TB,	Singh	N,	et	al.	Ex	vivo	 identification,	 isolation
and	analysis	of	tumor‐cytolytic	T	cells.	Nat Med.	2003;9:1377‐1382.
	38.	 Altman	JD,	Moss	PA,	Goulder	PJ,	et	al.	Phenotypic	analysis	of	anti‐
gen‐specific	T	lymphocytes.	Science.	1996;274:94‐96.
	39.	 Alter	G,	Malenfant	JM,	Altfeld	M.	CD107a	as	a	functional	marker	for
the	identification	of	natural	killer	cell	activity.	J Immunol Methods. 
2004;294:15‐22.
	40.	 Morgan	RA,	Dudley	ME,	Wunderlich	 JR,	 et	 al.	Cancer	 regression
in	 patients	 after	 transfer	 of	 genetically	 engineered	 lymphocytes.
Science.	2006;314:126‐129.
	41.	 Johnson	 LA,	 Morgan	 RA,	 Dudley	 ME,	 et	 al.	 Gene	 therapy	 with
human	 and	 mouse	 T‐cell	 receptors	 mediates	 cancer	 regression
and	 targets	 normal	 tissues	 expressing	 cognate	 antigen.	 Blood. 
2009;114:535‐546.
	42.	 Parkhurst	 MR,	 Yang	 JC,	 Langan	 RC,	 et	 al.	 T	 cells	 targeting	 car‐
cinoembryonic	 antigen	 can	 mediate	 regression	 of	 metastatic
colorectal	 cancer	 but	 induce	 severe	 transient	 colitis.	 Mol Ther. 
2011;19:620‐626.
	43.	 Morgan	RA,	Chinnasamy	N,	Abate‐Daga	D,	et	al.	Cancer	regression
and	neurological	toxicity	following	anti‐MAGE‐A3	TCR	gene	ther‐
apy.	J Immunother.	2013;36:133‐151.
	44.	 Robbins	PF,	Morgan	RA,	Feldman	SA,	et	al.	Tumor	regression	in	pa‐
tients	with	metastatic	 synovial	 cell	 sarcoma	and	melanoma	using
genetically	engineered	lymphocytes	reactive	with	NY‐ESO‐1.	J Clin 
Oncol.	2011;29:917‐924.
	45.	 Johnson	 LA,	 Heemskerk	 B,	 Powell	 DJ	 Jr,	 et	 al.	 Gene	 transfer	 of
tumor‐reactive	TCR	confers	both	high	avidity	and	tumor	reactivity	
to	nonreactive	peripheral	blood	mononuclear	cells	and	tumor‐infil‐
trating	lymphocytes.	J Immunol.	2006;117:6548‐6559.
SUPPORTING INFORMATION
Additional	 supporting	 information	 may	 be	 found	 online	 in	 the	
Supporting	Information	section	at	the	end	of	the	article.		
How to cite this article:	Shimizu	Y,	Yoshikawa	T,	Kojima	T,	
et	al.	Heat	shock	protein	105	peptide	vaccine	could	induce	
antitumor	immune	reactions	in	a	phase	I	clinical	trial.	Cancer 
Sci.	2019;110:3049‐3060.	https	://doi.org/10.1111/cas.14165	
【論文目録】
Ⅰ 主論文 
Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical 
trial. 
Shimizu Y., Yoshikawa T., Kojima T., Shoda K., Nosaka K., Mizuno S., Wada S., Fujimoto Y., Sasada 
T., Kohashi K., Bando H., Endo I., Nakatsura T:  
Cancer Science. 110: 3049-3060, 2019. Doi: 10.1111/cas.14165. 
Ⅱ 副論文 
なし
Ⅲ 参考文献 
Next-Generation Cancer Immunotherapy Targeting Glypican-3. 
Shimizu Y., Suzuki T., Yoshikawa T., Endo I., Nakatsura T:  
Front Oncol. 9: 248, 2019 
